CCO Independent Conference Coverage of the AASLD Conference 2020

November 13-16, 2020; Virtual
In this downloadable slideset, CCO’s expert faculty summarize emerging data on HBV management and treatment, discuss progress on identifying risk for hepatocellular carcinoma, and examine emerging trends in HCV treatment outcomes.
Norah Terrault Headshot
Norah Terrault, MD, MPH
Format: Microsoft PowerPoint (.ppt)
File Size: 4.4 MB
Released: November 25, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Educational grant provided by
Gilead Sciences

Related Content

Expert CCO commentary on how to incorporate noninvasive methods to assess fibrosis into management of patients with HBV infection

Paul Y. Kwo, MD Released: February 18, 2021

Watch this brief presentation by Dr. Paul Kwo on interpreting serology, HBV DNA, and fibrosis assessments to determine HBV treatment candidacy.

Paul Y. Kwo, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: February 16, 2021 Expired: February 15, 2022

Download free expert-authored slides reviewing AASLD guidance on HBV management pretreatment evaluation to determine treatment candidacy

Paul Y. Kwo, MD Released: February 16, 2021

CCO downloadable slides from Dr. Tatyana Kushner providing insights on updated guidance for HCV screening and management in women of childbearing age

Tatyana Kushner, MD, MSCE Released: January 8, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue